Trials and Research Search | SIU School of Medicine

Showing: 10 Results

Trial

Neurology

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

Trial

Neurology

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

Trial

Neurology

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Active recruiting

The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

Trial

Neurology

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Trial

Simmons Cancer Institute

KO-MEN-008: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Active recruiting

Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Trial

Neurology

Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.

Trial

Neurology

Supernus Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.

Trial

Neurology

UCB EP0162: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compar

Trial

Neurology

Xenon XPF-010-302: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal sei

Trial

Neurology

Xenon XPF-010-303: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Active recruiting

The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subj

Clinical trials and research studies